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AbstrAct
Background: Infections constitute a major problem for patients during oncological treatment or undergoing 
hematopoietic stem cell transplantation (HCT). 
Objective: The aim of the study was to analyze the epidemiology of viral infections in children during an-
ticancer therapy (PHO, pediatric haematology and oncology) or after HCT over a period of consecutive 
6 years in a single-centre study. 
Patients and methods: During this period, a total number of 182 HCTs were performed, and 306 children 
were newly diagnosed for malignancy. Incidence, hazard risk and outcome of infections were analyzed. 
Results: The cumulative incidence of viral infections was 61.7% in allo-HCT, 8.5% in PHO, and 4.1% in 
auto-HCT patients. The overall risk of viral infection in HCT patients was 17.3-fold higher (p < 0.0001) 
than in PHO patients. The risk was 30-fold higher for CMV and 63-fold higher for EBV, while the risk was 
comparable for influenza and adenovirus infection. Infections with polyoma BKV occurred only in HCT 
patients after allo-HCT. Factors contributing to increased risk of viral infections in allo-HCT patients both in 
uni- and multivariate analysis were: male sex, diagnosis of acute leukemia, alternative donor, CMV positive 
serostatus in recipient and/or donor, acute and chronic GVHD. All patients except two allo-HCT children 
survived viral infections. The cause of death were influenza and EBV-PTLD. 
Conclusions: The risk of viral infections in allo-HCT patients is much higher than in auto-HSCT and PHO 
patients, while the outcome of infections was better in the PHO and auto-HCT setting.
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Introduction
Infections constitute a major problem for patients 
during oncological treatment or undergoing hematopoi-
etic stem cell transplantation (HCT). Children with ma-
lignancies (PHO, pediatric hemato-oncology/oncology 
diseases) and after HCT are at risk of viral infections due 
to an impairment of the immune system. Factors predis-
posing a child to infection include alterations in the body’s 
natural barriers, the presence of central venous catheters, 
intensive chemotherapy, alterations in the innate immune 
system and acquired immunity. Due to clinical reasons, in 
HCT setting viral infections are divided as latent (herpes-
viruses, polyoma BKV) and sporadic (adenovirus – ADV, 
rotavirus – RV, influenza – FLU and others).
In immunocompromised patients, viruses cause 
double negative: direct and indirect effects. The direct 
effect of the virus depends on its lytic infection, such as 
pneumonia, gastro-intestinal disease, retinitis, hepatitis 
and myelosuppression. Indirect effects of the virus 
include immunosuppression and facilitating of fungal 
and bacterial infections. In HCT patients, viral infections 
can also cause graft failure, graft rejection and GVHD 
(graft-versus-host disease). These effects are most 
prominent for CMV infection, however, can occur also 
after other viral infections.
In a single-centre study in the USA, infections occur 
in 82% of children after allogeneic HCT (allo-HCT) [1], 
and in 49% of children with acute leukaemia [2]. Viral 
infections occurred in 11% of children undergoing au-
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to-HCT [2], and after allo-HCT in 20% of children before 
day +30, in 18% between days +30 until +100 and in 
19% after day +100 [1]. Among all allo-HCT infectious 
deaths, 24% were caused by viruses [1], while deaths 
due to infections were rare after auto-HCT [2]. Infections 
with cytomegalovirus (CMV) was one of the major risk 
factors for death after HCT [3–4].
The objective of the study was to analyze the inci-
dence and outcome of viral infections in children during 
anticancer therapy (PHO, pediatric hematology and 
oncology) or after HCT over a period of consecutive 
6 years in a single-center study.
Patients and methods
Patients. All consecutive patients undergoing treat-
ment for malignant diseases (PHO patients) or undergo-
ing HCT, treated in the Department of Pediatric Hema-
tology and Oncology and in the Department of Pediatric 
Surgery were included in this study. Data on viral infec-
tions diagnosed between 1.01.2012–31.12.2017 were 
reported and analyzed. In 2012–2013 the study was 
retrospective and from 2014 prospective.
Diagnosis of viral infections. Viral infections were 
classified as episodic (diagnosed on the basis of the 
clinical picture, and supplemented with appropriate 
tests), or latent ones (requiring monitoring at the mo-
lecular level) [5–7]. The following viruses were detected 
by PCR analysis: adenovirus (ADV), polyoma BKV, 
cytomegalovirus (CMV), Epstein-Barr Virus (EBV), hu-
man herpesvirus 6 (HHV-6) and influenza (FLU). The 
preemptive approach was introduced for infections 
with two latent viruses: CMV and EBV, only in allo-HCT 
patients, according to ECIL recommendations [6–7].
Anti-infective prophylaxis. Uniform, standard an-
ti-infective prophylaxis has been applied for patients 
in neutropenia and those undergoing HCT [6–9]. Em-
pirical, preemptive or targeted anti-infectious therapy 
was performed with various antibacterial, antiviral and 
antifungal agents according to commonly accepted 
strategies [6–11]. Additionally, environmental prophy-
laxis was applied in all centres.
Management of viral infections. The preemptive 
approach was introduced only for infections with two 
latent viruses: CMV and EBV, and only in allo-HCT 
patients, according to European ECIL recommenda-
tions. Since there are no existing recommendations to 
perform any other preemptive strategy for other viruses, 
and in other settings, especially in non-transplanted 
patients - in most cases, the diagnosis of viral infection 
was made on the basis of clinically-driven testing.
Statistical analysis. The infectious event was 
defined as the diagnosis of a first specific infectious 
disorder. Categorical variables were compared with 
the chi-square test, non-categorical variables were 
compared with the Mann-Whitney U test. Hazard risk 
(HR) and confidence intervals (CI) were calculated for 
the difference in the occurrence of infections in pa-
tients. Cumulative incidences of viral infections were 
calculated using competing risk analysis [12], starting 
from the day of transplant in the HCT setting, or the day 
of cancer diagnosis in the PHO setting, to the day of the 
first infection. Death was considered as the competing 
event. The Kaplan-Meier method was used to determine 
infection-related mortality and overall survival (OS) [13]. 
Multivariate models for the development of viral 
infections were calculated using the Cox model. 
Variables analyzed in HCT patients included age 
(≤ 10 years, > 10 years), sex (female, male), donor 
source (MSD, MUD/MMUD), disease (acute leukemia, 
other), conditioning intensity (myeloablative, other), 
donor/recipient CMV serostatus (negative/negative, any 
positive), acute GVHD as a time-dependent covariate 
occurring before infection onset (grade 0/1, grade 
2–4), and chronic GVHD as a time-dependent covariate 
occurring before infection onset (no, yes). Use of ATG 
(anti-thymocyte globulin) was the variable dependent 
on alternative donor, as it was used almost exclusively 
in MUD/MMUD transplants. Variables analyzed in PHO 
patients included age (≤ 10 years, > 10 years), sex 
(female, male) and disease (acute leukaemia, other). 
The stepwise selection procedure was used to select 
significant covariates. All reported p-values are two-sid-
ed; p < 0.05 was considered as statistically significant.
results
Demographics
Over an analyzed period of 72 consecutive months, 
a total number of 306 PHO patients were newly diagnosed 
for malignancy, including 81 with acute lymphoblastic leu-
kemia (ALL), 10 with acute myeloblastic leukemia (AML), 
30 with non-Hodgkin lymphoma (NHL), 32 with Hodgkin 
disease (HD), 48 with central nervous system tumors 
(CNS), 13 with neuroblastoma (NBL), 15 with Wilms tu-
mor (WT), 12 with Ewing sarcoma (ES) and 51 with other 
solid tumors (ST). During this period, a total number of 
182 HCTs were performed including 133 allo-HCTs and 
49 auto-HCTs. Children were transplanted due to ALL 
(n = 54), AML (n = 3), NHL/HD (n = 17), bone marrow 
failure syndromes (BMF, n = 19), primary immunodefi-
ciencies (PID, n = 11), neuroblastoma (NBL, n = 66), 
Ewing sarcoma (n = 18) or other diseases (n = 69). 
Incidence of infections
The cumulative incidence of viral infections be-
tween 2012–2017 in PHO patients was 8.5% (95% CI 
= 5.4–11.6), while in auto-HCT patients it was 4.1% 
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Figure 1. Cumulative incidence of viral in PHO and HCT settings with respect to time periods: (A) 2012–2013; 
(B) 2014–2015; (C) 2016–2017; (D) 2012–2017 together
(95% CI = 1.5–9.6) and in allo-HCT, it was 61.7% (95% 
CI = 53.4–69.9). Respective values for subsequent 
two-years periods are presented in Figure 1. 
The risk of viral infection in HCT patients was 
17.3-fold higher (p < 0.0001) than in PHO patients 
(Table 1). The risk was 30-fold higher for CMV (95% 
CI = 10–86; p < 0.0001) and 63-fold higher for EBV 
(95% CI = 8–477; p < 0.0001), while the risk was 
comparable for adenovirus infection (HR = 0.9; 95% 
CI = 0.4–2.4; p = 0.86), and influenza (HR = 2.3; 
95% CI = 0.3–16; p = 0.39). Infections with BKV 
occurred only in HCT patients after allo-HCT. In PHO 
patients, infections with EBV and HHV6 occurred only 
at diagnosis, thus should be treated as related to pri-
mary malignancy. Multiple viral infections occurred in 
4/133 (3.0%) allo-HSCT patients. 
With respect to the type of transplant, the cumulative 
incidence of viral infections was much higher after al-
lo-HCT than after auto-HCT: 61.7% vs 4.1% (HR = 37.7, 
95% CI = 8.8–162; p < 0.0001).
Most of the viral infections occurred within the first 
three months, both after allo-HCT and in PHO patients 
after diagnosis of the malignancy. The median time to 
first viral infection was the same after HCT and in the 
PHO patients after diagnosis of malignancy: 36 days 
vs 36 days, p = 0.99. Due to sporadic infections after 
auto-HCT, the respective comparison was not done. 
The incidence of viral infections in allo-HCT patients 
has increased in the most recent period (Figure 2A). The 
most frequent viral infections among allo-HCT patients 
were: CMV, EBV, BKV and ADV (Figure 2B). The inci-
dence of ADV infections was comparable in these three 
settings (Figure 2C), however, most of ADV infections 
were detected over a recent period (Figure 2D).
Risk factors of infections in allo-HCT patients
Factors contributing to increased risk of viral in-
fections both in uni- and multivariate analysis were: 
male sex, diagnosis of acute leukaemia, alternative 
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Table 1. Hazard risk of infections after HCT compared to PHO patients with respect to time periods
Infections Total 0–30 days 31–100 days 101–180 days 181–365 days > 365  
days
Allo-HCT Total
 ADV
 BKV
 CMV
 EBV
 FLU
82
6
13
38
23
2
28
4
5
17
2
0
33
0
6
15
10
2
8
0
2
2
4
0
9
1
0
3
5
0
4
1
0
1
2
0
Auto-HCT Total
 ADV
2
2
1
1
0
0
0
0
1
1
0
0
PHO Total
 ADV
 CMV
 EBV
 FLU
 HHV6
 PB19
26
15
4
1
2
3
1
10
4
0
1
1
3
1
9
6
2
0
1
0
0
5
3
2
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
Hazard risk
(HCT vs PHO)
HR = 17.3
95% CI = 10.2–29
p < 0.0001
HR = 7.9
95% CI = 3.7–16.8
p < 0.0001
HR = 10.9
95% CI = 5–23
p < 0.0001
HR = 3.8
95% CI = 1.2–12
p = 0.0012
HR = 11.0
95% CI = 2.3–51
p = 0.0005
N/A
HR – hazard risk; CI – confidence interval; p – p-value; N/A – not applicable
Figure 2. Cumulative incidence of viral in PHO and HSCT settings with respect to time periods: (A) in allo-HCT; (B) for 
CMV, EBV, BKV and ADV infections; (C) for ADV infections in PHO and HCT patients between 2012–2017; (D) for ADV 
infections in PHO and HCT patients between 2016–2017.
Przemysław Gałązka et al., Viral infections in PHO and HCT children
131www.journals.viamedica.pl/medical_research_journal
donor (other than matched family donor), CMV 
positive serostatus in recipient and/or donor, acute 
and chronic GVHD. Table 2 provides the results of 
a multivariate analysis comparing infections among 
the different risk factors (Table 2). Viral infections 
were also less likely after non-myeloablative or re-
duced-intensity conditioning however it did not reach 
statistical significance. 
Survival after viral infections
All PHO patients and all but two HCT patients sur-
vived viral infections. Two patients after HCT clearly 
died due to infectious complications: after influenza 
infection, and after EBV-PTLD. Nevertheless, several 
other patients with CMV reactivation proceeded to 
invasive fungal diseases and deceased. The treat-
ment and outcome of viral infections are shown in 
Table 3.
Table 2. Risk factor analysis for viral infections in allo-HCT patients
Variable Characteristics Univariate analysis Multivariate analysis
Frequency p-value RR 
(95% CI)
p-value
Sex Female
Male
25/51 (49.0%)
57/82 (69.5%)
0.018 1
2.3 (1.1–4.9)
0.029
Age < 10 years
> 10 years
40/67 (59.7%)
42/66 (63.6%)
0.640 1
1.1 (0.5–2.4)
0.770
Disease Other 
Acute leukemia
8/46 (17.4%)
74/87 (85.1%)
< 0.0001 1
27 (10–70)
< 0.0001
Donor MFD
other
11/33 (33.3%)
71/100 (71.0%)
< 0.0001 1
4.8 (2.1–11)
0.0002
Conditioning Myeloablative
Other
54/79 (68.4%)
28/54 (51.9%)
0.054 1
0.5 (0.2–1.1)
0.081
CMV serostatus 
(donor/recipient)
Both negative
Other
1/8 (12.5%)
81/125 (64.8%)
0.003 1
12 (1.5–108)
0.010
Acute GVHD No
Yes
57/102 (55.9%)
25/31 (80.6%)
0.013 1
3.3 (1.2–8.7)
0.023
Chronic GVHD No
Yes
64/113 (56.6%)
18/20 (90.0%)
0.004 1
6.9 (1.5–31)
0.009
GVHD – graft-versus-host-disease; MFD – matched family donor; RR – relative risk
Discussion
In this paper, we report the results of a single-centre 
study of the risk and outcome of viral infections in pedi-
atric HCT and PHO patients. All patients in respective 
groups were treated with the same therapeutic proto-
cols, using comparable principles of supportive therapy. 
The two main messages came from this study: first 
– that the risk of viral infections after allo-HCT is very 
high, especially for patients with acute leukaemia; and 
the second – that the outcome of viral infections in PHO 
and HCT pediatric patients is good. On the other hand, 
the risk of viral infections after auto-HCT is the same 
as it is during conventional chemotherapy for pediatric 
malignancies. 
The four viruses which show the highest incidence 
in allo-HCT patients are CMV, BKV, EBV and ADV. 
In comparison to results obtained in the report of 
a 2-year nationwide study of infections in pediatric 
Table 3. Viral infections in allo-HCT patients
 Infection N Age [years] 
(median, range)
Time to infection [months] 
(median, range)
Treatment Survival 
rate
CMV 38 10.7 (2.7–18) 1.1 (0.7–13.2) Ganciclovir, foscarnet, cidofovir 38/38
EBV 23 9.2 (2.4–18) 2 (0.8–13.0) Rituximab 22/23
BKV 13 12.7 (7.1–18) 1.3 (0.8–4.1) Cidofovir 13/13
ADV 6 7.4 (1.9–12.1) 0.9 (0.2–13.7) Cidofovir or symptomatic 6/6
FLU 2 9.3 (3.6–14.9) 1.7 (1.4–2) Oseltamivir 1/2
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hemato-oncology and stem cell transplant centres 
[14], it should be mentioned that the profile of viral 
infections in allo-HCT setting is comparable over cal-
endar time and similar with respect to other pediatric 
HCT centres [1]. 
The three viruses with the highest incidence in al-
lo-HCT patients belong to latent infections: CMV, BKV 
and EBV. Infections with these viruses are related to 
the impairment of recipient immune system, resulting 
mainly in a reactivation of latent infections in allo-HCT 
patients. Comparison of the incidence of viral infections 
in PHO, auto-HCT, and allo-HCT patients shows that it 
refers to the substantial differences in immunological 
impairment after allo-HCT. With the very high worldwide 
prevalence of CMV and EBV infection, these two viruses 
still remain major threats aggravating morbidity and 
mortality after allo-HCT [6,7,15–17].
It is currently estimated that the median rate of CMV 
reactivation is about 37% after allogeneic transplant and 
12% after autologous transplant, while 5% in patients 
with nontransplant haematological malignancies, 30% 
in solid organ transplant recipients, and 21% in patients 
with primary immunodeficiencies [18]. The summary of 
the published data shows that CMV disease occurred 
in 13.9% of CMV-seropositive recipients and in 1.7% of 
CMV-seronegative recipients of allo-HCT [18]. 
The median reported the incidence of EBV reactivation 
after allo-HCT is 29.4%, with the range between 0.1–63% 
and is largely dependent on the type of transplant, 
EBV assay sensitivity, defined level of EBV-DNA-emia, 
use of systematic screening, and its timing [19]. The 
overall incidence of EBV-related PTLD (post-transplant 
lymphoproliferative disorder) after allo-HCT is estimated 
to be 3.2% [16,19].
Infection with polyoma BKV occurs in 8–25% of 
pediatric and 7–54% of adult recipients undergoing 
allo-HCT. Age of the HCT recipient > 7 years is re-
garded as a risk factor for BKV reactivation [20]. CMV 
or human herpesvirus 6 (HHV6) viremia facilitates BKV 
hemorrhagic cystitis [21].
The reported frequency of invasive ADV infections 
in the allo-HCT setting is considerably higher in pedi-
atric patients (6–42%) than in adults (3–15%), but the 
clinical manifestations can be equally severe [22–23]. 
With these data, probably the incidence of communi-
ty-acquired respiratory viral (CARV) infections, including 
ADV, is underestimated in our centre, as just with the im-
provement diagnostics towards ADV over last two years, 
the incidence of ADV infections relatively increased.
Despite much progress in understanding the 
pathogenesis, epidemiology and risk factors of CMV, 
EBV, BKV, and ADV, infections with these viruses or 
their reactivations still represent a major unmet clin-
ical need with limited prophylactic and therapeutic 
options. To overcome this deficiency novel antiviral 
treatment approaches supported by proper clinical 
trials are necessary.
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